Ruti Aga: Six Years, Two for the Substance and Four for the Prescription

On a September evening the ledger lay open on my Pune rooftop, and it had two columns. In the left column I wrote: substance found in the sample, two years. In the right: document altered, four years. Beneath them the total: six years, running from 10 September. In the margin I put the age — 32. I capped the pen and the chai went cold. Most readers of the Ruti Aga case stop at the substance. I did not stop there. I stopped at the arithmetic, because the arithmetic tells you where the weight of this story actually sits. Of six years, only two belong to what she took. Four belong to the piece of paper she produced. This is not a doping report; it is a report on a medical-governance failure, and having spent three decades keeping ledgers on athletes who live or die by a sheet nobody else bothered to write, I treat that failure as seriously as a positive sample. First, what is established. According to the Athletics Integrity Unit statement, Aga won a half marathon in China in March and her sample tested positive for methylprednisolone. She had been provisionally suspended since 10 September, and now carries a six-year ban. The source does not give the year of the March race, the ban's end date, her finishing time, her splits, or the strength of the field. What is not given, I will not invent. Her record, though, is not new to anyone who keeps a Major scoreboard. She won the 2026 Tokyo Marathon and finished second at three World Marathon Majors. My own notebooks carry her against Berlin 2026 (second) and Tokyo 2026 (first), in the 2:18–2:20 class — those numbers come from my old sheets, not from the AIU statement, so treat them as pending verification and, by my own rule, do not build a conclusion on them. What is safe: the 2026 Tokyo title, three Major second places, age 32. The source does not say what tier that Chinese half marathon was. One technical fact matters more. In road racing the in-competition testing window opens at 23:59 the day before the race. An injection given days earlier is therefore caught if residue remains on race day. That window is the hinge on which this entire case turns. A correction belongs here, in the second paragraph rather than the tenth, because without it everything downstream is misread. Early reports called methylprednisolone a "prohibited steroid" and said WADA classes it as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid (S1). And S9 is prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection out of competition is entirely legal. It becomes a violation only if residue is present in competition. That single sentence changes the case. The question is not whether she took a steroid. The question is route, timing, and whether real records existed for the treatment. Intra-articular methylprednisolone for knee synovitis is ordinary sports-medicine practice in distance runners; the files of the javelin coaches I worked with at Patiala carry exactly such notes. That clinical plausibility was her strongest defence. It collapsed the moment the prescription turned out to be fabricated. Per the AIU statement, Aga cited a knee injury and produced a prescription. Three separate checks failed. The clinic named on the document did not exist. The person who wrote it was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned the claim. Three independent verification failures on one sheet of paper. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician and without any TUE infrastructure. Note where the four years came from. The tampering charge was built not on the document alone but on statements made during an investigative interview. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention — that is my observation, not the source's claim, and I keep it separate because it is unproven. Now the arithmetic. Two years for presence, four for tampering, six total. The structure is standard, not exceptional: four years is the Code's standard tampering sanction, and a two-year presence sanction implies a Specified Substance finding without proven intent. What puzzles me is why the panel declined the no-significant-fault mitigation. The answer is plain — a forged prescription is itself circumstantial evidence of concealment intent. Aga destroyed precisely the defence that could have worked. Genuine records, correct route, correct washout timing: possibly no case at all. Backdating to 10 September is procedural housekeeping, not relief. Provisional suspension time counts against the ban; the athlete gains nothing real. Here I have to argue against my own instinct. The easy read is "another East African caught." That read is wrong, because it inflates the chemistry beyond its importance. Methylprednisolone is not EPO. Glucocorticoids have no established endurance benefit; they reduce inflammation and mask pain, which is exactly why they are the cheapest, most available tool for an injured marathoner. The day I write this up as performance-enhancing doping is the day I sell my own ledger ethics. The truth is that six years were imposed on paper, not on a chemical. And that is the real signal: the enforcement frontier has moved from detection to document verification. When an agency starts checking whether a clinic exists, whether the prescriber is registered, whose pad it was, the axis of sanction changes. Athletes running without a medical team carry that risk, and the risk comes from management, not from the vial. Now the boring number, which I will not dodge. Ethiopia's women's marathon depth is such that world-record class sits at the top and a 2:18 performer is not automatically selectable. Aga's three Major second places are commercial-tier results, not global championship medals. The removal of a 32-year-old changes Ethiopian medal capacity by nothing measurable. That is dull and it is true. I learned on a Kolkata sports desk two decades ago to read the paper before the shouting, and the paper says exactly this. The Chinese label-race circuit deserves its own line. For East African marathoners it is a high-appearance-fee, low-risk income tier between Majors. It is also now the AIU's highest-yield testing ground. The economics of appearance fees and the economics of testing are colliding in the same races, and that collision will produce more files. A sampling note, because I impose it on myself. My ledger holds no data on Ethiopian training clusters. I never counted the club-agent structure on the ground; I only recorded results. What the sheet cannot see is absent from this file — training partners, agents, the person who may have advised a family member to play doctor. The AIU names only the family member. Whether an agent or manager was investigated is unknown. Whether the Ethiopian federation said anything is unknown; the source carries only the AIU statement, not one line from a national body. That silence is information, and I log it as missing data rather than as empty space. One warning to myself. The proportionality argument will be made both ways: six years for a substance with no proven endurance benefit, cited as proof of AIU rigour and as proof of uneven enforcement against African road runners. I do not have the reasoned decision. Until I do, I will not settle that argument, because a number I have not personally reconciled is a number I do not print. What I will watch: the disqualification scope in the reasoned decision — the March result and its prize money are almost certainly void, though the source never says so; whether a CAS appeal is filed within the roughly twenty-one-day window, though a document-based finding is hard to overturn; and most importantly whether any visible layer of TUE and medical-record management appears in road-running entourages. If it does not, the next prescription will also come off someone's old pad. I am a monk of small numbers, and the rooftop is my chapel. The smallest number left in my diary that evening was not six. It was two — age 32, return 38. In the depth of Ethiopian women's marathon, how many races does a 38-year-old with a doping file on her record win? I am asking. I will not answer.